We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here
for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Clone 1O19 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects O-GlcNAc transferase. It targets an epitope within 20 amino acids from the internal region.
KLH-conjugated linear peptide corresponding to 20 amino acids from the internal region of human O-GlcNAc transferase.
Quality Control Testing
Evaluated by Western Blotting in NIH3T3 cell lysate.
Western Blotting Analysis: A 1:10,000 dilution of this antibody detected O-GlcNAc Transferase in NIH3T3 cell lysate.
Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected O-GlcNAc Transferase in HeLa, MCF-7, and L6 cell lysates.
Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected O-GlcNAc Transferase in HeLa, A431, HepG2, NIH3T3 cells.
Affinity Binding Assay: A representative lot of this antibody bound O-GlcNAc Transferase with a KD of 3.5 x 10-8 in an affinity binding assay.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected O-GlcNAc Transferase in human pancreas tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Anti-O-GlcNAc Transferase, clone 1O19 ZooMAb®, Cat. No. ZRB1323, is a recombinant Rabbit monoclonal antibody that targets O-GlcNAc Transferase and is used in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry, and Western Blotting.
UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit (UniProt: O15294; also known as EC:184.108.40.206, O-GlcNAc transferase subunit p110, O-linked N-acetylglucosamine transferase 110 kDa subunit, OGT) is encoded by the OGT gene (Gene ID: 8473) in human. O-GlcNAc transferase is highly expressed in pancreas and is detected in nucleus, cytoplasm, and plasma membrane. A mitochondrial isoform (isoform 2) has also been described that associates with the inner mitochondrial membrane and is reported to be cytotoxic and triggers apoptosis in several cell types, including INS1, an insulinoma cell line. O-GlcNAc transferase catalyzes the transfer of a single N-acetylglucosamine from UDP-GlcNAc to a serine or threonine residue in cytoplasmic and nuclear proteins resulting in their modification with a b-linked N-acetylglucosamine (O-GlcNAc). It glycosylates a large and diverse number of proteins including histone H2B, Akt1, enhancer of zeste homolog 2 (EZH2), phosphofructokinase, host cell factor C1 etc., and can regulate their cellular processes via cross-talk between glycosylation and phosphorylation. It is also involved in insulin resistance in muscle and adipocyte cells via glycosylating insulin signaling components and inhibiting the threonine 308 phosphorylation of Akt1. Altered glycosylation of O-GlcNAc transferase has been implicated in diabetes and Alzheimer s disease. O-GlcNAcylation of Akt1 affects insulin signaling and contributes to diabetes complications. Mutations in OGT gene have also been liked to X-linked mental retardation that is characterized by impairments in adaptive behavior. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Daou, S., et al. (2011). Proc. Natl. Acad. Sci. USA. 108(7); 2747-2752; Shin, SH., et al. (2011). Amino Acids. 40(3); 885-893).
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb® formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.